sansrosa articles ↓

The path from the laboratory for Sansrosa / COL-118 / CD07805/47 to a product that realises the promise of permanently reducing  a red face has been a long one. We first heard about a product to become known …

The recruiting manager from Frontage Clinical is looking for participants in the trial they are hosting for rosacea redness. Frontage Clinical in Hackensack, NJ is conducting a research study to evaluate the safety of an investigational topical gel medication for moderate to severe facial redness associated with ROSACEA. All qualified participants will receive at no cost …

In yet more proof that Galderma wants to sit on the drug known as Sansrosa, a new August 2010 Phase II dose finding study has been listed at clinicaltrials.gov. This latest trial will compare Sansrosa, or CD07805/47 as Galderma now calls it, in strengths of 0.5% and 0.18% against a placebo containing just the vehicle gel. A total of 260 patients will be …

Signum Biosciences have announced that their first generation “Signal Transduction Modulator” product, AFC Medirepair (Arazine), is now officially available in Japan. From the product web site, the product has some other related products names such as Skin …

News across the business web sites today a new company obtaining funding for a patent protected alpha-adrenergic receptor based treatment for the redness of rosacea.

Vicept Therapuetics is based in Malvern in Pennsylvania and is a privately held company.
From Fidelity Biosciences Joins $10M Series A for Vicept Therapeutics

“We are delighted by the strong investor interest in this round of financing which will allow us to …